Cargando…
Correction to: Evaluation of Cardiovascular Disease Risk in HIV‑1–Infected Patients Treated with Darunavir
Autores principales: | Opsomer, Magda, Dimitrova, Dessislava, Verspeelt, Johan, Purrington, Amy, Mehbob, Abdul, Chavers, Scott, Pai, Helen, Vanveggel, Simon, Luo, Donghan, Brown, Kimberley, Moecklinghoff, Christiane, Nettles, Richard E., Boven, Katia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131123/ https://www.ncbi.nlm.nih.gov/pubmed/30079430 http://dx.doi.org/10.1007/s40268-018-0243-y |
Ejemplares similares
-
Evaluation of Cardiovascular Disease Risk in HIV-1–Infected Patients Treated with Darunavir
por: Opsomer, Magda, et al.
Publicado: (2018) -
Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults
por: Arathoon, Eduardo, et al.
Publicado: (2014) -
Prevalence of Darunavir Resistance in the United States from 2010 to 2017
por: Brown, Kimberley, et al.
Publicado: (2018) -
Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial
por: Arathoon, Eduardo, et al.
Publicado: (2017) -
A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
por: Eron, Joseph J., et al.
Publicado: (2018)